A major new initiative led by Mark Zuckerberg and Priscilla Chan is set to push the boundaries of artificial intelligence in biology, with a $500 million investment aimed at building detailed AI models of human cells.
The project, announced by their research organisation Chan Zuckerberg Biohub, will run over five years and seeks to create the tools and datasets needed to simulate how human cells function in both healthy and diseased states. The group says the data generated will be made freely available to scientists around the world.
Researchers involved in the effort believe that AI-powered models could transform the study of disease by allowing experiments to be conducted digitally at a scale not currently possible in laboratories. If successful, such models could help uncover how diseases develop and guide the creation of new treatments.
The Biohub was founded in 2016 to bring together engineers and scientists to better understand biology at the cellular level. Since then, it has built extensive datasets focused on individual cells and developed computing systems designed for biological research.
The latest investment includes $400 million allocated to internal work and an additional $100 million set aside to support external researchers. Among the project’s partners is Nvidia, which will contribute expertise in high-performance computing.
According to Biohub scientists, one of the biggest challenges facing the project is the need for vast amounts of data. AI systems become more accurate as they are trained on larger and more detailed datasets, but current biological data remains limited.
Alex Rives, the organisation’s head of science, said new technologies will be required to observe cells in greater detail, from molecular structures to how they behave in tissues. He noted that understanding the full complexity of biology will demand far more data than is currently available.
The initiative reflects a broader shift across the life sciences sector, where artificial intelligence is increasingly being used to speed up research and drug development. Companies and research groups are exploring how machine learning can help identify patterns in biological systems and predict how diseases progress.
Other technology firms are also expanding into this field. Isomorphic Labs is working on AI-driven drug discovery, while Microsoft has developed models for medical imaging and genomics.
Backers of the Biohub project say collaboration will be key to success, with hopes that additional funding from other organisations will help expand the effort. The long-term goal is ambitious: to use the combination of AI and biology to improve understanding of disease and accelerate the development of treatments on a global scale.